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Previewshigh ROS levels (Benani et al., 2007; An-
drews et al., 2008; Horvath et al., 2009;
Jaillard et al., 2009). Repeated activation
of POMC neurons and related behaviors
and autonomic adaptations occur daily.
Short-term ROS peaks appear to be
fundamental for evoking a proper behav-
ioral, endocrine, and autonomic response
to nutrient intake and are likely to be asso-
ciated with short-term peaks of ROS
generation in sympathetic neurons as
well. On the other hand, prolonged expo-
sure to hyperglycemia-triggered ROS
clearly impairs sympathetic neuronal
functions and outflow due to oxidation of
the Cys residue of cholinergic receptors
(Campanucci et al., 2010). Whether sim-
ilar impairments of receptor activation
(not necessarily cholinergic receptors)
occur in POMC neurons in response to
sustained ROS generation, when an ani-
mal is on high fat diet for example, is a
highly relevant question to pursue.In summary, the observations of Cam-
panucci et al. (2010) shed new light on
the etiology and offer potential new thera-
peutic approaches for diabetic neuropa-
thies. Questions remain, however, regard-
ing the source of ROS that impair nAchRs
function: whether ROS are from intracel-
lular or extracellular origin and whether
ROS are the product of glucose oxidation
or emerge from other metabolic pro-
cesses. Further work is also needed to
clarify whether effects of neuropathies
promoted by diabetes influence hepatic
glucose production and output and how
restoration of sympathetic outflow would
impact these critical processes.REFERENCES
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Disabled-1 is a key signalingmolecule in the Reelin pathway that plays a critical role in neuronalmigration and
positioning during brain development. In this issue of Neuron, Yano et al. demonstrate that the neuron-
specific RNA binding protein Nova2 contributes to neuronal migration by regulating alternative splicing of
disabled-1.Neuronal migration and positioning in the
developing brain is a complicated pro-
cess that requires well-orchestrated inter-
actions among migrating neurons, radial
glial cells, and postmigration neurons.
The Reelin pathway controls neuronal
migration in the developing cortex, cere-
bellum, and hippocampus, and it has
been implicated in human brain disorders
such as lissencephaly, schizophrenia,
bipolar disorder, autism, and temporal
lobe epilepsy. Genetic and biochemical
studies have helped elucidate the bio-
chemical mechanisms responsible for
Reelin signaling (for review, see Rice andCurran 2001; Ayala et al., 2007). Reelin is
a protein ligand that binds two receptors:
apoER2 and VLDLR. Binding of Reelin to
these receptors triggers tyrosine phos-
phorylation of disabled-1 (Dab1) by Fyn
and Src. Tyrosine phosphorylated Dab1
recruits downstream signaling molecules
including the SH2/SH3 domain-contain-
ing adaptor proteins, Crk and CrkL, as
well as other signaling components,
before it is degraded by the ubiquitin-pro-
teasome pathway. These adaptor
proteins induce cytoskeletal changes
and other cellular responses necessary
for appropriate migration and positioningof neurons. Therefore, Dab1 plays
a central role in Reelin signaling, and
failure of either expression or phosphory-
lation of Dab1 leads to severe defects in
neuronal migration, similar to those
observed in the absence of Reelin or
Reelin receptors. In this issue of Neuron,
Yano et al. present a novel mechanism
of Dab1 regulation involving alternative
splicing by Nova2.
Nova2 is an RNA-binding protein
specifically expressed in neurons. It was
identified as an autoantigen in paraneo-
plastic opsoclonus myoclonus ataxia
(POMA) (Yang et al., 1998), a neurologic66, June 24, 2010 ª2010 Elsevier Inc. 811
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Figure 1. Alternative Splicing of Dab1 and Neuronal Migration in the Developing Brain
(A) In situ hybridization analysis of E15 mouse brain from www.chopbgem.org. Note that expression
of Nova2 is weak in the ventricular and intermediate zone of the cortex (yellow arrow) and in the cerebellum
(blue arrow), relative to that of Dab1.
(B) Expression of Dab1 and its splice variant Dab1.7bc in the developing mouse brain.
(C) RNA processing of Dab1 and neuronal migration in wild-type and Nova2 null mice. In wild-type mice,
Nova2 binds to YCAYmotifs immediately upstream of exons 7b and 7c, leading to skipping of these exons
during splicing. In Nova2 null mice, exons 7b and 7c are incorporated intomRNA, leading to the addition of
33 amino acids juxtaposed to the phosphotyrosine residues. Dab1.7bc inhibits neuronal migration by
unknown mechanisms.
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Previewsdisorder characterized by ataxia and
tremors—phenotypes that are character-
istic of mice with defects in the Reelin
pathway. POMA results from an autoim-
mune attack against antigens expressed
by tumor cells that are also present in
normal neurons. Using antibodies from
patient sera, they identified Nova2, as
well as Nova1, as autoantigens respon-
sible for disease. Nova2 is a sequence-
specific RNA-binding protein that is highly
expressed in neurons in the developing
and postnatal brain, suggesting a unique
function in regulating RNA processing
in neuronal cells. To identify RNAs to
which Nova binds, Darnell and colleagues
purified protein-RNA complexes using
ultraviolet cross-linking and immunopre-
cipitation (CLIP). CLIP analysis led them
to identify target transcripts alternatively
transcribed by Nova, as well as map the
RNA binding sites involved in exon exclu-
sion or inclusion (Ule et al., 2003, 2006).
Here, Yano et al. (2010) examine Nova2
null mouse brain to determine whether
laminar structures are formed normally.
They found that Cux1-positive cortical
neurons, usually positioned in neuronal812 Neuron 66, June 24, 2010 ª2010 Elsevielayers II-IV, are mislocalized underneath
layer V in Nova2 null mice (Figure 1C).
Early generated neurons such as ER81-
positive neurons, normally destined to
form layer V, also exhibited mild mislocal-
ization in the subventricular zone. The
results demonstrate that migration of
late-generated neurons is severely
affected in the absence of Nova2, while
early-generated neurons are only mildly
affected. Based on the information pre-
sented by Yano et al. (2010), it seems
unlikely that the preplate fails to split into
the marginal zone and the subplate as
the marginal zone is not crowded in
Nova2 null mice. Failure of preplate split-
ting and accumulation of cells in the
marginal zone are hallmarks of reeler,
Dab1 null, and other Reelin pathway
mutant mice (Rice et al., 1998; Park and
Curran, 2008). Therefore, Nova2 null
mice may exhibit a partial neuronal migra-
tion defect distinct from that observed in
Reelin pathway mutant mice. The authors
also find that only 30% of Purkinje
neurons failed to migrate, remaining
within cerebellar white matter, in Nova2
null mice. Additional histological studiesr Inc.will shed light on these processes in
Nova2 null mice, and it will be interesting
to determine whether layer formation
and dendritic development occur nor-
mally in the hippocampus, since these
processes are defective in reeler and in
mice lacking Crk and CrkL (Park and
Curran, 2008).
Yano et al. (2010) also investigate the
underlying mechanism whereby Nova2
contributes to neuronal migration. Nova2
is a RNA-binding protein previously
shown to regulate alternative splicing.
The authors utilized the approach they
developed, high-throughput sequencing
of RNAs isolated by CLIP (HITS-CLIP), to
identify RNA targets of Nova2 in the
developing mouse brain. Among 20 tran-
scripts encoding Reelin and other
proteins involved in migration, only Dab1
showed highly significant splicing
changes in Nova2 null embryos. RT-PCR
analysis of wild-type cortex revealed the
presence of both Dab1 and its splice
variant, Dab1.7bc. Dab1.7bc includes 17
amino acids from exon 7b and 16 amino
acids from exon 7c in addition to the
complete 555 amino acids of Dab1
(Figure 1C). Expression of Dab1.7bc is
dramatically reduced at E14.5, and
completely absent at E16.5 through P10,
indicating that it undergoes temporal
regulation during brain development
(Figure 1B). In Nova2 null mice, Dab1.7bc
is dramatically increased from E10
through E16.5, suggesting that Nova2
suppresses expression of Dab1.7bc
during late stages of embryonic develop-
ment. To assess whether Nova2 directly
acts on Dab1 RNA to exclude exons 7b
and 7c, Yano et al. (2010) mutated
Nova2 binding cis-acting elements
(YCAY motifs) immediate upstream of
exons 7b and 7c and carried out reporter
minigene assays in 293T cells. Cotrans-
fection with Nova2 blocked inclusion of
exons 7b and 7c in Dab1; however, muta-
tion of the YCAY motifs selectively in-
hibited this effect. These results clearly
indicate that Nova2 directly suppresses
inclusion of Dab1.7bc.
To address whether neuronal migration
defects in the absence of Nova2 are
a consequence of increased Dab1.7bc
expression, Yano et al. (2010) employed
an in utero electroporation approach.
Remarkably, electroporation of E14.5
cortex with Dab1.7bc caused a neuronal
Neuron
Previewsmigration defect similar to that seen
in Nova2 null mice. Furthermore, electro-
poration with wild-type Dab1 overcame
the neuronal migration defect in Nova2
null mice. These reciprocal experiments
suggest that Dab1 and Dab1.7bc act
antagonistically to regulate neuronal mi-
gration. Thus, neuronal migration defects
can be attributed to either a decrease in
Dab1 or an increase in Dab1.7bc. When
these two conditions occur simulta-
neously, the defect is enhanced.
It should be noted that, unlike reeler
mice, neuronal migration is not com-
pletely disrupted in the cerebral cortex
and cerebellum in the absence of Nova2.
Many Cux1-positive cells migrated nor-
mally in Nova2 null mice (Figure 1C).
A comparison of the gene expression
patterns of Nova2 and Dab1 in the devel-
oping brain provides a clue to explain this
discrepancy. According to both immu-
nostaining results by Yano et al. (2010)
and in situ hybridization data from www.
chopbgem.org (Magdaleno et al., 2006),
Nova2 is expressed mainly in the cortical
plate of the developing cortex. On the
other hand, Dab1 is expressed in the
ventricular zone as well as the cortical
plate and the intermediate zone. Nova2
expression appears to be relatively lower
than that of Dab1 in the developing cere-
bral cortex and cerebellum (Figure 1A).
Therefore, it is possible that either Nova2
must reach a critical level of expression
to affect a subpopulation of neurons
during migration or that it influences
neuronal migration independently of the
Reelin pathway. In situ hybridization anal-
ysis using probes specific for exons 7b
and 7c would be helpful to address this
issue further.
An important question remains con-
cerning the mechanism whereby
Dab1.7bc inhibits neuronal migration.
Although the authors show that Dab1.7bc
can be tyrosine phosphorylated by Src
causing it to form a complex with Crk in
293T cells, it is unclear whether thishappens during neuronal migration in the
Nova2 null embryonic cortex. In 293T
cells, Dab1.7bc was not degraded upon
tyrosine phosphorylation in the presence
of ectopic Src, suggesting that, unlike
Dab1, it might be resistant to degradation
by the ubiquitin-proteasome pathway.
Failure of Dab1 protein degradation and
its accumulation is a good indicator of
ectopic neurons, since elevated levels
of Dab1 proteins were observed in
displaced neurons in reeler (Rice et al.,
1998). However, the defect in neuronal
migration observed in the absence of
Nova2, or in the presence of Dab1.7bc,
is different from the excess migration
defect observed in mice when the E3
ubiquitin ligase cullin 5 is ablated and
active Dab1 accumulates in migrating
neurons (Feng et al., 2007). The pheno-
type of Nova2 null mice is more akin to
that of ApoER2 knockout mice, in which
late-generated neurons fail to migrate.
Therefore, it is important to determine
whether the Dab1.7bc protein level is
elevated in developing mouse brain.
The findings presented by Yano et al.
(2010) suggest that the in-frame addition
of 33 amino acids in Dab1 causes
a conformation change that disrupts its
function in the Reelin pathway. Because
Dab1.7bc induces a defect in neuronal
migration in the presence of Dab1 in the
in utero electroporation assay, Dab1.7bc
may act in a dominant-negative manner.
This is possible if Dab1.7bc preserves its
ability to bind Reelin receptors upon
Reelin stimulation while losing the ability
to interact with Src family tyrosine kinases
and other downstreammolecules such as
Crk and CrkL (Figure 1C). However, we
cannot rule out another possibility that
Dab1.7bc gains a new function that
inhibits neuronal migration independently
of Reelin signaling. Structural analyses
could address the conformational change
in the PTB and phosphotyrosine domains
of Dab1.7bc. In addition, further func-
tional analyses may shed light on whetherNeurontyrosine residues in Dab1.7bc are phos-
phorylated and capable of interacting
with Crk and CrkL in vivo.
The work by Yano et al. (2010) provides
a telling example of how HITS-CLIP anal-
ysis can be applied to identify targets of
RNA-binding proteins with biological
significance. The authors establish a novel
mechanism for the control of neuronal
migration by alternative splicing. In addi-
tion to posttranslational modification,
alternative splicing of key signaling
proteins, such as Dab1, provides a fine-
tuning approach to modulation of com-
plex biological processes like neuronal
migration in a temporal and spatial
pattern. Similar approaches may be fruit-
ful to investigate other complex events
that contribute to the development and
function of the mammalian brain.REFERENCES
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